Katelyn Brown

2.6k total citations · 2 hit papers
23 papers, 1.8k citations indexed

About

Katelyn Brown is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Katelyn Brown has authored 23 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Katelyn Brown's work include Diabetes Treatment and Management (14 papers), Diabetes Management and Research (10 papers) and Metabolism, Diabetes, and Cancer (7 papers). Katelyn Brown is often cited by papers focused on Diabetes Treatment and Management (14 papers), Diabetes Management and Research (10 papers) and Metabolism, Diabetes, and Cancer (7 papers). Katelyn Brown collaborates with scholars based in United States, United Kingdom and Spain. Katelyn Brown's co-authors include Laura Fernández Landó, Juan P. Frías, Xuewei Cui, Brandon K. Bergman, Bing Liu, Melanie J. Davies, Federico C. Pérez Manghi, Julio Rosenstock, Ángel Rodríguez and Ross Bray and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Katelyn Brown

23 papers receiving 1.7k citations

Hit Papers

Tirzepatide versus Semaglutide Once Weekly in Patients wi... 2021 2026 2022 2024 2021 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
    2021 1.1k citations Juan P. Frías, Melanie J. Davies et al. New England Journal of Medicine profile →
  2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
    2021 411 citations Bernhard Ludvik, Francesco Giorgino et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katelyn Brown United States 10 1.4k 603 575 445 414 23 1.8k
Breno Edson Sendão Alves Brazil 6 1.1k 0.8× 346 0.6× 751 1.3× 409 0.9× 657 1.6× 9 1.9k
Rafael Violante Ortíz Denmark 6 1.3k 0.9× 403 0.7× 1.1k 1.9× 375 0.8× 635 1.5× 11 1.8k
Daniel R. Quast Germany 12 1.1k 0.8× 501 0.8× 285 0.5× 468 1.1× 257 0.6× 31 1.6k
Tuğçe Kalaycı Oral United States 5 1.3k 0.9× 410 0.7× 724 1.3× 425 1.0× 524 1.3× 8 1.9k
Mads Axelsen Denmark 7 968 0.7× 523 0.9× 338 0.6× 396 0.9× 208 0.5× 14 1.7k
Liana K. Billings United States 14 963 0.7× 536 0.9× 421 0.7× 338 0.8× 335 0.8× 48 1.6k
Kirstine Brown‐Frandsen United States 5 1.2k 0.9× 411 0.7× 581 1.0× 383 0.9× 390 0.9× 12 1.7k
Matthew Wintle United States 12 1.4k 1.0× 637 1.1× 308 0.5× 582 1.3× 163 0.4× 18 1.6k
Frank Vercruysse United States 19 1.7k 1.2× 583 1.0× 493 0.9× 931 2.1× 261 0.6× 24 2.1k
Thomas Blevins United States 23 2.3k 1.7× 724 1.2× 441 0.8× 954 2.1× 216 0.5× 55 2.6k

Countries citing papers authored by Katelyn Brown

Since Specialization
Citations

This map shows the geographic impact of Katelyn Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katelyn Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katelyn Brown more than expected).

Fields of papers citing papers by Katelyn Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katelyn Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katelyn Brown. The network helps show where Katelyn Brown may publish in the future.

Co-authorship network of co-authors of Katelyn Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Katelyn Brown. A scholar is included among the top collaborators of Katelyn Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katelyn Brown. Katelyn Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Block, Christophe De, Juan P. Frías, Clare J. Lee, et al.. (2024). Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel. 19(S 01). S78–S78. 1 indexed citations
2.
Frías, Juan P., et al.. (2024). Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). The Journal of Clinical Endocrinology & Metabolism. 109(7). 1745–1753. 11 indexed citations
3.
Nicholls, Stephen J., Santiago Tofé, Carel W. le Roux, et al.. (2024). Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program. Cardiovascular Diabetology. 23(1). 63–63. 4 indexed citations
4.
5.
Gelhorn, Heather L., Katelyn Brown, Melissa Ross, et al.. (2023). The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient Preference and Adherence. Volume 17. 793–805. 2 indexed citations
6.
Lingvay, Ildiko, Ofri Mosenzon, Katelyn Brown, et al.. (2023). Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology. 22(1). 66–66. 37 indexed citations
7.
Boye, Kristina S., Vivian T. Thieu, Hélène Sapin, et al.. (2023). Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Therapy. 14(11). 1833–1852. 10 indexed citations
8.
Mullins, Garrett R., Michael E. Hodsdon, Greg Anglin, et al.. (2023). Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. The Journal of Clinical Endocrinology & Metabolism. 109(2). 361–369. 4 indexed citations
9.
Brown, Katelyn, et al.. (2023). A Large-Scale, Multiplayer Virtual Reality Deployment: A Novel Approach to Distance Education in Human Anatomy. Medical Science Educator. 33(2). 409–421. 23 indexed citations
10.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2022). EFFICACY AND SAFETY OF TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR AGONIST, COMPARED TO INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3). Diabetologie und Stoffwechsel. 17(S 01). S30–S30. 1 indexed citations
11.
Frías, Juan P., Melanie J. Davies, Julio Rosenstock, et al.. (2022). Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). Diabetologie und Stoffwechsel. 17(S 01). S21–S22. 1 indexed citations
12.
Frías, Juan P., Melanie J. Davies, Julio Rosenstock, et al.. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 385(6). 503–515. 1112 indexed citations breakdown →
13.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 398(10300). 583–598. 411 indexed citations breakdown →
14.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2021). 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3). Diabetes. 70(Supplement_1). 5 indexed citations
15.
Frías, Juan P., Melanie J. Davies, Julio Rosenstock, et al.. (2021). 84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). Diabetes. 70(Supplement_1). 3 indexed citations
16.
Brown, Katelyn, et al.. (2021). Engaging Rural High School Students in STEM Utilizing Graduate Mentors, Virtual Reality and Case‐based Learning. The FASEB Journal. 35(S1). 2 indexed citations
17.
Brown, Katelyn, et al.. (2021). A Large‐Scale Virtual Reality Deployment for Distance Education in Human Anatomy. The FASEB Journal. 35(S1). 1 indexed citations
18.
19.
Brown, Katelyn & John B. Hertig. (2016). Determining Current Insulin Pen Use Practices and Errors in the Inpatient Setting. The Joint Commission Journal on Quality and Patient Safety. 42(12). 568–AP7. 8 indexed citations
20.
Brown, Katelyn, et al.. (2015). Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients. Clinical Pediatrics. 54(11). 1102–1106. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Breno Edson Sendão Alves Breakdown of academic impact, for papers by Rafael Violante Ortíz Breakdown of academic impact, for papers by Daniel R. Quast Breakdown of academic impact, for papers by Tuğçe Kalaycı Oral Breakdown of academic impact, for papers by Mads Axelsen Breakdown of academic impact, for papers by Liana K. Billings Breakdown of academic impact, for papers by Kirstine Brown‐Frandsen Breakdown of academic impact, for papers by Matthew Wintle Breakdown of academic impact, for papers by Frank Vercruysse Breakdown of academic impact, for papers by Thomas Blevins
Rankless by CCL
2026